Grundläggande statistik
| CIK | 1031516 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Merus Labs International Inc
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| July 29, 2017 |
Merus Labs International FORM 15-12G 15-12G 1 form15-12g.htm FORM 15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(G) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 000-30082 MERUS LABS INTERNATIONAL INC. |
|
| July 20, 2017 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 form6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2017 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toro |
|
| July 20, 2017 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 NOTICE OF CHANGE IN CORPORATE STRUCTURE Pursuant to Section 4.9 of National Instrument 51-102 Continuous Disclosure Obligations Item 1 Names of the Parties to the Transaction Merus Labs International Inc. (“Merus”) and Norgine B.V. (“Norgine”). Item 2 Description of the Transaction Pursuant to a statutory plan of arrangement (the “Arrangement”) under section |
|
| July 17, 2017 |
Merus Labs International FORM RW RW 1 formrw.htm FORM RW July 17, 2017 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Re: Merus Labs International Inc. Application for Withdrawal of Registration Statement on Form F-10, File No. 333-205589 Ladies and Gentlemen: Pursuant to Rule 477 (“Rule 477”) under the Securities Act of 1933, as amended (the “Securities Act”), |
|
| July 13, 2017 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) Merus Labs International Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2017 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Welling |
|
| July 13, 2017 |
Merus Labs International Inc.: Exhibit 99.1 - Filed by newsfilecorp.com Merus Labs International Inc. Receives Court Approval in Connection with Proposed Plan of Arrangement with Norgine B.V. TORONTO, Ontario ? July 12, 2017 ? Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) (?Merus? or the ?Company?) announced today that the Supreme Court of British Columbia has issued a final order approvi |
|
| July 10, 2017 |
EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 MERUS LABS INTERNATIONAL INC. (THE “CORPORATION”) REPORT OF VOTING RESULTS (Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations) This report discloses the matter voted upon and the outcome of the votes at the special meeting of shareholders of the Corporation held on July 10, 2017 (the “Meeting”). The matter is described in greater |
|
| July 10, 2017 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Merus Labs International Inc. Shareholders Approve Plan Of Arrangement with Norgine B.V. TORONTO, Ontario, AMSTERDAM, The Netherlands — July 10, 2017 — Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) (“Merus” or the “Company”) announced that at a special meeting of shareholders held earlier today (the “Meeting”), Merus shareholders voted in favour of t |
|
| July 10, 2017 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2017 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Address o |
|
| July 6, 2017 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) Merus Labs International Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2017 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellin |
|
| July 6, 2017 |
Merus Labs International Inc. - Exhibit 99.1 - Filed by newsfilecorp.com Merus Labs International Inc. and Norgine B.V. receive Spanish anti-trust approval of proposed Arrangement TORONTO, Ontario ? July 3, 2017 ? Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) (?Merus? or the ?Company?) and Norgine B.V. (?Norgine?) announced today that Norgine?s proposed acquisition of all of the issued an |
|
| June 28, 2017 |
Merus Labs International Inc. - Exhibit 99.1 - Filed by newsfilecorp.com Merus Labs International Inc. Mails Letter to Shareholders with Reminder to Vote FOR the Proposed Arrangement with Norgine B.V. by deadline of 10:00 AM (Toronto time) July 6, 2017, and Receives Positive Recommendation in Favour of the Arrangement from Independent Proxy Advisor ISS. TORONTO, Ontario June 27, 2017 Merus Lab |
|
| June 28, 2017 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) Merus Labs International Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellin |
|
| June 28, 2017 |
The Board UNANIMOUSLY recommends that Shareholders vote FOR the Arrangement. Merus Labs International Inc. - Exhibit 99.2 - Filed by newsfilecorp.com T 905.726.0995 | F 416.593.4434 | www.meruslabs.com Suite 2110,100 Wellington Street, Toronto, ON, M5K1H1 Trading Symbols: TSX and NASDAQ ? MSL Important Reminder to Vote FOR The Proposed Arrangement with Norgine B.V. by deadline of 10:00 AM (Toronto Time) July 6, 2017 June 27, 2017 Dear Shareholders: This letter is being sen |
|
| June 12, 2017 |
MSLI / Merus Labs International Inc / 1832 Asset Management L.P. - SC 13G/A Passive Investment 1832 Asset Management L.P.: Form SC 13G - Merus Labs - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Year End Filing)* - AMENDMENT** - there is a correction to the common share number MERUS LABS INTERNATIONAL INC. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 59047R101 (CUSIP |
|
| June 12, 2017 |
MSLI / Merus Labs International Inc / 1832 Asset Management L.P. - SC 13G Passive Investment 1832 Asset Management L.P.: Form SC 13G - Merus Labs - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Exit Filing)* MERUS LABS INTERNATIONAL INC. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 59047R101 (CUSIP Number) May 31, 2017 (Date of Event Which Requires Filing of this St |
|
| June 6, 2017 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Address o |
|
| June 6, 2017 |
EX-99.3 4 exhibit99-3.htm EXHIBIT 99.3 This document is important and requires your immediate attention. If you are in any doubt as to how to deal with it, you should consult with your investment dealer, broker, lawyer or other professional advisor. This document does not constitute an offer or a solicitation to any person in any jurisdiction in which such offer or solicitation is unlawful. If you |
|
| June 6, 2017 |
EX-99.4 5 exhibit99-4.htm EXHIBIT 99.4 |
|
| June 6, 2017 |
FIRST AMENDMENT TO ARRANGEMENT AGREEMENT FIRST AMENDMENT TO ARRANGEMENT AGREEMENT This First Amendment dated June 1, 2017. AMONG: MERUS LABS INTERNATIONAL INC., a corporation incorporated under the laws of British Columbia (hereinafter referred to as the Company) - and - NORGINE B.V., a private company with limited liability incorporated under the laws of the Netherlands, and having trade register number 30127007 and its registered add |
|
| June 6, 2017 |
MERUS LABS INTERNATIONAL INC. NOTICE OF SPECIAL MEETING OF SHAREHOLDERS to be held on July 10, 2017 EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 MERUS LABS INTERNATIONAL INC. NOTICE OF SPECIAL MEETING OF SHAREHOLDERS to be held on July 10, 2017 NOTICE IS HEREBY GIVEN that a special meeting (the “Meeting”) of the holders (“Shareholders”) of common shares (the “Shares”) of Merus Labs International Inc. (the “Company”) will be held at the offices of Torys LLP, 79 Wellington St. West, 33rd Floor, TD South |
|
| June 6, 2017 |
Merus Labs International Inc. - Exhibit 99.6 - Filed by newsfilecorp.com MERUS LABS INTERNATIONAL INC. Certificate Pursuant to National Instrument 54-101 Communication with Beneficial Owners of Securities of a Reporting Issuer TO: CANADIAN SECURITIES REGULATORY AUTHORITIES Merus Labs International Inc. (the ?Corporation?) hereby certifies, pursuant to paragraph 2.20(c) of National Instrument 54-10 |
|
| June 6, 2017 |
EX-99.7 8 exhibit99-7.htm EXHIBIT 99.7 Merus Labs International Inc. files Management Information Circular for Proposed Acquisition by Norgine B.V. Acquisition with Significant Premium to Merus Shareholders Arrangement Affords Opportunity to Realize Immediate and Certain Fair Cash Value for Shares TORONTO, Ontario — June 5, 2017 — Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) (“Merus” or |
|
| June 6, 2017 |
******************************** - 2 - LETTER OF TRANSMITTAL EX-99.5 6 exhibit99-5.htm EXHIBIT 99.5 THIS LETTER OF TRANSMITTAL IS FOR USE IN CONNECTION WITH THE PLAN OF ARRANGEMENT INVOLVING MERUS LABS INTERNATIONAL INC. AND NORGINE B.V. THIS LETTER OF TRANSMITTAL MUST BE VALIDLY COMPLETED, DULY EXECUTED AND RETURNED TO THE DEPOSITARY, COMPUTERSHARE INVESTOR SERVICES INC. IT IS IMPORTANT THAT YOU VALIDLY COMPLETE, DULY EXECUTE AND RETURN THIS LETTER OF TRAN |
|
| June 2, 2017 |
Merus Labs International Inc. - Exhibit 99.1 - Filed by newsfilecorp.com MERUS LABS INTERNATIONAL INC. OBTAINS INTERIM ORDER FOR PLAN OF ARRANGEMENT TORONTO, Ontario ? June 1, 2017 ? Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) (?Merus? or the ?Company?) announced today that it has obtained an interim order of the Supreme Court of British Columbia. The interim order authorizes Merus to, |
|
| June 2, 2017 |
To: All Canadian Securities Regulatory Authorities Merus Labs International Inc. - Exhibit 99.2 - Filed by newsfilecorp.com 510 Burrard St, 3rd Floor Date: May 16, 2017 Vancouver BC, V6C 3B9 www.computershare.com To: All Canadian Securities Regulatory Authorities Subject: MERUS LABS INTERNATIONAL INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Special M |
|
| June 2, 2017 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 form6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2017 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toro |
|
| May 19, 2017 |
MERUS LABS INTERNATIONAL INC. NORGINE B.V. Merus Labs International Inc.: Exhibit 99.2 - Filed by newsfilecorp.com EXECUTION COPY MERUS LABS INTERNATIONAL INC. and NORGINE B.V. ARRANGEMENT AGREEMENT May 11, 2017 TABLE OF CONTENTS ARTICLE 1 INTERPRETATION 1 Section 1.1 Defined Terms 1 Section 1.2 Certain Rules of Interpretation 12 ARTICLE 2 THE ARRANGEMENT 14 Section 2.1 Arrangement 14 Section 2.2 Interim Order 14 Section 2.3 The Company Me |
|
| May 19, 2017 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 form6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toron |
|
| May 19, 2017 |
FORM 51-102F3 MATERIAL CHANGE REPORT Merus Labs International Inc. - Exhibit 99.1 - Filed by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT 1. NAME AND ADDRESS OF COMPANY Merus Labs International Inc. (?Merus?) 100 Wellington St. West Suite 2110, PO Box 151 Toronto, ON M5K 1H1 Canada 2. DATE OF MATERIAL CHANGE May 11, 2017 3. NEWS RELEASE Merus issued a news release, attached as Schedule ?A?, disclosing the material change thr |
|
| May 11, 2017 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4667296k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 T |
|
| May 11, 2017 |
Merus Labs Reports Fiscal Q2 2017 Results Exhibit 99.1 Merus Labs Reports Fiscal Q2 2017 Results ? Gross Basis Revenue of $25.9 million in fiscal Q2 2017 ? Adjusted EBITDA of $9.4 million in fiscal Q2 2017 ? Conference call to take place on May 11, 2017 at 8:30 a.m. ET TORONTO, May 11, 2017 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] announced its financial results for the second quarter of fi |
|
| May 11, 2017 |
Exhibit 99.2 MERUS LABS INTERNATIONAL INC. MANAGEMENT?S DISCUSSION AND ANALYSIS For the three and six months ended March 31, 2017 and 2016 This Management?s Discussion and Analysis (the ?MD&A?) sets out the financial performance, results of operations and condition of Merus Labs International Inc. (the ?Company? or ?Merus?) for the three and six months ended March 31, 2017 (?Q2 2017?) compared to |
|
| May 11, 2017 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2017 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Address o |
|
| May 11, 2017 |
Merus Labs and Norgine Enter into a Definitive Arrangement Agreement Exhibit 99.1 Merus Labs and Norgine Enter into a Definitive Arrangement Agreement ? Norgine to acquire all outstanding shares of Merus for $1.65 per share in cash TORONTO and AMSTERDAM, May 11, 2017 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") TSX: MSL, NASDAQ: MSLI and Norgine B.V. ("Norgine") announced today that they have entered into a definitive agreement (the "Arrangement |
|
| March 1, 2017 |
CORRESP 1 filename1.htm Reply to the Attention of Michael H. Taylor* Direct Line 604.691.7410 Direct Fax 604.893.2669 Email Address [email protected] Our File No. 62498V-0001 Date March 1, 2017 Via EDGAR Correspondence United States Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. United States of America 20549 Attention: Mr. Jim B. Rosenberg Senior Assistant Chief A |
|
| February 15, 2017 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2017 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 15 |
|
| February 15, 2017 |
EX-99.2 3 ex992.htm Q1 REPORT Exhibit 99.2 Merus Labs International Inc. First Quarter Report Fiscal 2017 For the Three Months Ended December 31, 2016 and 2015 MERUS LABS INTERNATIONAL INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three months ended December 31, 2016 and 2015 This Management’s Discussion and Analysis (the “MD&A”) sets out the financial performance, results of operations and co |
|
| February 15, 2017 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Michael Bumby, Chief Financial Officer of Merus Labs International Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Merus Labs International Inc. (the ?issuer?) for the interim period ended December 31, 2016; 2. No misrepresentati |
|
| February 15, 2017 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.3 4 ex993.htm CEO CERTIFICATION Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Barry Fishman, Chief Executive Officer of Merus Labs International Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Merus Labs International Inc. (the “issuer”) for the interim period ended De |
|
| February 15, 2017 |
Merus Labs Reports Fiscal Q1 2017 Results Exhibit 99.1 Merus Labs Reports Fiscal Q1 2017 Results ? Gross Basis Revenue of $30.9 million in fiscal Q1 2017 ? Adjusted EBITDA of $10.8 million in fiscal Q1 2017 ? Conference call on February 14, 2017 at 8:30 a.m. ET TORONTO, Feb. 14, 2017 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] announced its financial results for the first quarter of fiscal 201 |
|
| January 5, 2017 |
MSLI / Merus Labs International Inc / 1832 Asset Management L.P. - SC 13G Passive Investment SC 13G 1 sch13gmerus.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Year End Filing)* MERUS LABS INTERNATIONAL INC. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 59047R101 (CUSIP Number) December 31, 2016 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| December 29, 2016 |
EX-99.2 3 v455918ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Merus Labs International Inc. Annual Report Fiscal 2016 For the Years Ended September 30, 2016 and 2015 Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of Merus Labs International Inc. and its subsidiaries: We have audited the accompanying consolidated financial statements of Merus Labs Interna |
|
| December 29, 2016 |
EX-99.1 2 v455918ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ANNUAL INFORMATION FORM FOR THE YEAR-ENDED SEPTEMBER 30, 2016 DECEMBER 29, 2016 MERUS LABS INTERNATIONAL INC. 100 Wellington St. West, Suite 2110 Toronto, Ontario, Canada M5K 1H1 TABLE OF CONTENTS INTRODUCTORY NOTES 3 The Company 3 Date of Information 3 Currency 3 Cautionary Note Regarding Forward Looking Statements 3 CORPORATE STRUCTURE 6 Corp |
|
| December 29, 2016 |
Merus Labs International FORM 40-F 40-F 1 v45591840f.htm FORM 40-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 40-F ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2016 Commission File Number: 000-30082 MERUS LABS INTERNATIONAL I |
|
| December 20, 2016 |
EX-99.3 4 ex993.htm MDA - SEPTEMBER 30, 2016 Exhibit 99.3 MERUS LABS INTERNATIONAL INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the year ended September 30, 2016 and 2015 This Management’s Discussion and Analysis (the “MD&A”) sets out the financial performance, results of operations and condition of Merus Labs International Inc. (the “Company” or “Merus”) for the fiscal year ended September 30, 2 |
|
| December 20, 2016 |
EX-99.2 3 ex992.htm AFS - SEPTEMBER 30, 2016 Exhibit 99.2 Merus Labs International Inc. Annual Report Fiscal 2016 For the Years Ended September 30, 2016 and 2015 Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of Merus Labs International Inc. and its subsidiaries: We have audited the accompanying consolidated financial statements of Merus Labs Int |
|
| December 20, 2016 |
Merus Labs Reports Fiscal Q4 and 2016 Results EX-99.1 2 ex991.htm NEWS RELEASE DATED DECEMBER 14, 2016 Exhibit 99.1 Merus Labs Reports Fiscal Q4 and 2016 Results · Gross Basis Revenue of $111.4 million in F16 · Adjusted EBITDA of $43.2 million in F16 · Seven additional legacy products acquired · Strengthened organization and infrastructure · Conference call to take place at 8:30 a.m. ET TORONTO, Dec. 14, 2016 /CNW/ - Merus Labs International |
|
| December 20, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Addr |
|
| November 17, 2016 |
Merus Receives Nasdaq Notice Regarding Minimum Bid Price Requirements Exhibit 99.1 Merus Receives Nasdaq Notice Regarding Minimum Bid Price Requirements TORONTO, Nov. 16, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") (TSX: MSL, NASDAQ: MSLI) announced that it has received written notification from The NASDAQ Stock Market LLC ("Nasdaq") that it is not in compliance with the minimum bid price requirement of US $1.00 per share. This does not imp |
|
| November 17, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 15 |
|
| August 18, 2016 |
EX-99.1 2 v446961ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Merus Labs International Inc. Third Quarter Report Fiscal 2016 For the Three and Nine Months Ended June 30, 2016 and 2015 MERUS LABS INTERNATIONAL INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three and nine months ended June 30, 2016 and 2015 The following section of our report sets forth Management’s Discussion and Analysis of the financi |
|
| August 18, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Addres |
|
| August 18, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Addres |
|
| August 18, 2016 |
EX-99.1 2 v446961ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Merus Labs International Inc. Third Quarter Report Fiscal 2016 For the Three and Nine Months Ended June 30, 2016 and 2015 MERUS LABS INTERNATIONAL INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three and nine months ended June 30, 2016 and 2015 The following section of our report sets forth Management’s Discussion and Analysis of the financi |
|
| August 18, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Addres |
|
| August 18, 2016 |
Exhibit 99.1 Merus Labs International Inc. Third Quarter Report Fiscal 2016 For the Three and Nine Months Ended June 30, 2016 and 2015 MERUS LABS INTERNATIONAL INC. MANAGEMENT?S DISCUSSION AND ANALYSIS For the three and nine months ended June 30, 2016 and 2015 The following section of our report sets forth Management?s Discussion and Analysis of the financial performance and condition of Merus Lab |
|
| August 18, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Addres |
|
| August 18, 2016 |
Exhibit 99.1 Merus Labs International Inc. Third Quarter Report Fiscal 2016 For the Three and Nine Months Ended June 30, 2016 and 2015 MERUS LABS INTERNATIONAL INC. MANAGEMENT?S DISCUSSION AND ANALYSIS For the three and nine months ended June 30, 2016 and 2015 The following section of our report sets forth Management?s Discussion and Analysis of the financial performance and condition of Merus Lab |
|
| August 16, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Addres |
|
| August 16, 2016 |
Merus Labs Reports Fiscal Q3 2016 Results Exhibit 99.1 Merus Labs Reports Fiscal Q3 2016 Results ? Gross Basis Revenue of $32.6 million, an increase of 138% over Q3 2015 ? Adjusted EBITDA of $12.0 million, an 88% increase over Q3 2015 ? Conference call at 8:30 a.m. ET on August 15, 2016 TORONTO, Aug. 15, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] today announced its financial results for |
|
| August 16, 2016 |
Merus Labs Reports Fiscal Q3 2016 Results Exhibit 99.1 Merus Labs Reports Fiscal Q3 2016 Results ? Gross Basis Revenue of $32.6 million, an increase of 138% over Q3 2015 ? Adjusted EBITDA of $12.0 million, an 88% increase over Q3 2015 ? Conference call at 8:30 a.m. ET on August 15, 2016 TORONTO, Aug. 15, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] today announced its financial results for |
|
| August 16, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Addres |
|
| August 11, 2016 |
Exhibit 99.1 Merus Labs to Present at U.S. Investor Conference and Announces Date of Fiscal Q3 2016 Earnings Release TORONTO, Aug. 10, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] announced today that it will release its earnings for the third quarter of fiscal 2016 before the market opens on Monday, August 15, 2016 and hold a conference call at 8: |
|
| August 11, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Addres |
|
| July 5, 2016 |
Merus Announces Reduced Leverage and Provides Business Update EX-99.1 2 ex991.htm PRESS RELEASE DATED JULY 4TH, 2016 Exhibit 99.1 Merus Announces Reduced Leverage and Provides Business Update TORONTO, July 4, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") (TSX: MSL, NASDAQ: MSLI) is pleased to announce that it has made the first of its regularly scheduled quarterly principal repayments under its new credit facility and to provide a gen |
|
| July 5, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 To |
|
| July 5, 2016 |
Merus Labs Appoints Two New Senior Executives EX-99.1 2 ex991.htm PRESS RELEASE DATED JUNE 30TH, 2016 Exhibit 99.1 Merus Labs Appoints Two New Senior Executives TORONTO, June 30, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") (TSX: MSL, NASDAQ: MSLI) is pleased to announce two key additions to its executive leadership team effective July 1, 2016. Dr. Michael Bumby is appointed Chief Financial Officer (CFO) succeeding Mr |
|
| July 5, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 To |
|
| June 7, 2016 | ||
| June 7, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 To |
|
| June 7, 2016 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Merus Labs International Inc. (the ?Company? or ?Merus?) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 Item 2 Date of Material Change March 1, 2016 and March 7, 2016 Item 3 News Release The news release announcing the closing of the bought deal financing of Subscription Receipts was i |
|
| June 7, 2016 |
EX-99.2 3 ex992.htm SUBSCRIPTION RECEIPT AGREEMENT DATED MARCH 1, 2016 Exhibit 99.2 UNDERWRITING AGREEMENT March 1, 2016 Merus Labs International Inc. 100 Wellington St. West Suite 2110, P.O. Box 151 Toronto, ON M5K 1H1 Attention: Barry Fishman, Chief Executive Officer & Director Dear Sirs/Mesdames: Canaccord Genuity Corp. (“Canaccord”) and Clarus Securities Inc. (“Clarus” and collectively with Ca |
|
| May 18, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Address o |
|
| May 18, 2016 |
Merus Labs International Inc. Announces Deemed Exercise of Special Warrants Exhibit 99.1 Merus Labs International Inc. Announces Deemed Exercise of Special Warrants TORONTO, May 18, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") (TSX: MSL, NASDAQ: MSLI) is pleased to announce today the deemed exercise of the Company's 14,250,000 outstanding special warrants (the "Special Warrants") into 14,250,000 common shares (the "Common Shares"). The Special War |
|
| May 18, 2016 |
MERUS LABS INTERNATIONAL INC. BUSINESS ACQUISITION REPORT FORM 51-102F4 Exhibit 99.1 MERUS LABS INTERNATIONAL INC. BUSINESS ACQUISITION REPORT FORM 51-102F4 Item 1. Identity of Company 1.1 Name and Address of Company Merus Labs International Inc. (the ?Company? or ?Merus?) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 1.2 Executive Officer The following executive officer of the Company is knowledgeable about the significant acquisition an |
|
| May 18, 2016 |
Merus Labs International 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Address o |
|
| May 18, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4402866k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 T |
|
| May 18, 2016 |
EX-99.2 3 v440286ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 MERUS LABS INTERNATIONAL INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three and six months ended March 31, 2016 and 2015 The following section of our report sets forth Management’s Discussion and Analysis of the financial performance and condition of Merus Labs International Inc. (“the Company” or “Merus”) for the three and six months ende |
|
| May 18, 2016 |
Merus Labs Reports Fiscal Q2 2016 Results Exhibit 99.1 Merus Labs Reports Fiscal Q2 2016 Results · Net Revenue of $19.7 million, a 55% increase over Q2 2015 · Adjusted EBITDA of $11.0 million, an 17% increase over Q2 2015 · Conference call at 8:30 a.m. ET on May 12, 2016 TORONTO, May 11, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] today announced its financial results for its second quart |
|
| March 31, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Address |
|
| March 31, 2016 |
Exhibit 99.2 Merus Labs International Inc. March 30, 2016 British Columbia Securities Commission Alberta Securities Commission Saskatchewan Financial Services Commission Manitoba Securities Commission Ontario Securities Commission Autorit? des march?s financiers New Brunswick Securities Commission Prince Edward Island Office of the Attorney General Dear Sirs: Re: Merus Labs International Inc. Repo |
|
| March 31, 2016 |
Merus announces re-election of directors Exhibit 99.1 Merus announces re-election of directors TORONTO, March 30, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] reported today the results of its 2016 annual general meeting of shareholders held on March 30, 2016. All directors nominated as listed in the Company's management information circular dated February 26, 2016 were re-elected as memb |
|
| March 7, 2016 |
Exhibit 99.1 Merus Completes Acquisition of Surgestone?, Provames?, Tredemine? and Speciafoldine? Rights from Sanofi TORONTO, March 7, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] announced today that it has completed the previously announced acquisition of rights to Surgestone?, Provames?, Tredemine? and Speciafoldine? in France and select other m |
|
| March 7, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 T |
|
| March 4, 2016 |
Exhibit 99.1 Merus Labs International Inc. 100 Wellington St. West, Suite 2110 Toronto, Ontario M5K 1H1 NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 30, 2016 AND INFORMATION CIRCULAR February 26, 2016 This document requires immediate attention. If you are in doubt as to how to deal with the documents or matters referred to in this Information Circular, you should immediatel |
|
| March 4, 2016 |
EX-99.3 7 ex993.htm FORM OF PROXY Exhibit 99.3 |
|
| March 4, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Address |
|
| March 4, 2016 |
Exhibit 99.4 |
|
| March 4, 2016 |
EX-99.2 6 ex992.htm NOTICE OF MEETING Exhibit 99.2 MERUS LABS INTERNATIONAL INC. 100 Wellington Street West, #2110 Toronto, Ontario M5K 1H1 Telephone: (416) 593-3725 NOTICE OF ANNUAL GENERAL MEETING TO THE SHAREHOLDERS OF MERUS LABS INTERNATIONAL INC.: NOTICE IS HEREBY GIVEN that an annual general meeting (the “Meeting”) of the holders (the ”Shareholders”) of common shares of Merus Labs Internatio |
|
| March 3, 2016 |
Merus Labs International Inc. Announces Closing Of $27 Million Bought Deal Financing Exhibit 99.1 Merus Labs International Inc. Announces Closing Of $27 Million Bought Deal Financing TORONTO, March 1, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") (TSX: MSL, NASDAQ: MSLI) is pleased to announce today the closing of its previously announced bought deal financing of subscription receipts (the "Offering") with a syndicate of investment dealers (the "Underwriter |
|
| March 3, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 T |
|
| February 23, 2016 |
Merus Labs International Form 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 15 |
|
| February 23, 2016 |
Merus Announces Inaugural Deal with Sanofi Exhibit 99.1 Merus Announces Inaugural Deal with Sanofi TORONTO, Feb. 23, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] announced today that it has entered into an agreement with Sanofi S.A. to acquire the rights to Surgestone?, Provames?, Speciafoldine?, and Tredemine? in France. Surgestone? and Provames?, are used in a variety of women's health in |
|
| February 22, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 15 |
|
| February 22, 2016 |
Merus announces $27 million bought deal Exhibit 99.1 Merus announces $27 million bought deal TORONTO, Feb. 19, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] has entered into an agreement with a syndicate of underwriters (collectively, the "Underwriters") to purchase, on a bought deal private placement basis, 14,250,000 subscription receipts of the Company (the "Subscription Receipts"), at |
|
| February 18, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Addr |
|
| February 18, 2016 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Merus Labs International Inc. (the ?Company? or ?Merus?) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 Item 2 Date of Material Change February 1, 2016 and February 4, 2016 Item 3 News Release The news release announcing the execution of the product acquisition agreement and the amende |
|
| February 18, 2016 |
first AMENDED AND RESTATED CREDIT AGREEMENT EX-99.3 4 ex993.htm FIRST AMENDED AND RESTATED CREDIT AGREEMENT Exhibit 99.3 [Execution Copy] first AMENDED AND RESTATED CREDIT AGREEMENT This Agreement dated February 1, 2016 is made among: MERUS LABS INTERNATIONAL INC. as Borrower - and - THE LENDERS FROM TIME TO TIME PARTY TO THIS AGREEMENT as Lenders - and - BANK OF MONTREAL as Co-Lead Arranger, Sole Bookrunner and Administrative Agent - and - |
|
| February 18, 2016 |
Exhibit 99.2 EXECUTION COPY 4 February 2016 UCB PHARMA GMBH as Seller and MERUS LABS LUXCO II S.A. R.L. as Purchaser and MERUS LABS INTERNATIONAL INC. as Purchaser Guarantor SALE AND PURCHASE AGREEMENT in relation to certain pharmaceutical products and related assets CONTENTS Clause Page 1. DEFINITIONS 4 2. SALE AND PURCHASE OF THE BUSINESS ASSETS 13 3. PRICE 15 4. EXCHANGE 16 5. INTENTIONALLY DEL |
|
| February 12, 2016 |
Exhibit 99.2 Merus Labs International Inc. First Quarter Report 2016 For the Three Months Ended December 31, 2015 and 2014 1 MERUS LABS INTERNATIONAL INC. MANAGEMENT?S DISCUSSION AND ANALYSIS For the three months ended December 31, 2015 and 2014 The following section of our report sets forth Management?s Discussion and Analysis of the financial performance and condition of Merus Labs International |
|
| February 12, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 15 |
|
| February 12, 2016 |
MSLI / Merus Labs International Inc / Goodwood Inc. Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 MERUS LABS INTERNATIONAL INC. |
|
| February 12, 2016 |
Merus Labs Reports Solid Fiscal Q1 2016 Results Exhibit 99.1 Merus Labs Reports Solid Fiscal Q1 2016 Results · Net Revenue of $15.9 million, a 50% increase over Q1 2015 · Adjusted EBITDA of $8.5 million, an 13% increase over Q1 2015 · Conference call at 8:30 a.m. ET on February 12, 2016 TORONTO, Feb. 11, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] today announced its financial results for its f |
|
| February 10, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 15 |
|
| February 10, 2016 |
EX-99.1 2 ex991.htm NEWS RELEASE DATED FEBRUARY 4, 2016 Exhibit 99.1 Merus completes acquisition of Elantan®, Isoket® and Deponit® rights from UCB and announces date of Q1 2016 earnings release TORONTO, Feb. 4, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] announced today that it has completed the previously announced acquisition of rights to Elanta |
|
| February 2, 2016 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February 2016 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Addr |
|
| February 2, 2016 |
Merus Reaches Agreement to Acquire Three Cardiovascular Products Exhibit 99.1 Merus Reaches Agreement to Acquire Three Cardiovascular Products TORONTO, Feb. 1, 2016 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] announced today that it has entered into an agreement with UCB to acquire rights to Elantan?, Isoket? and Deponit? in Europe and select other markets (the "Acquisition"). These products belong to a category of |
|
| January 11, 2016 |
MSLI / Merus Labs International Inc / 1832 Asset Management L.P. - SC 13G Passive Investment 1832 Asset Management L.P.: Form SC 13G - Merus Labs - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Year End Filing)* MERUS LABS INTERNATIONAL INC. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 59047R101 (CUSIP Number) December 31, 2015 (Date of Event Which Requires Filing o |
|
| December 30, 2015 |
Merus Labs International FORM 40-F 40-F 1 v42805840f.htm FORM 40-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 40-F ¨ REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OR x ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2015 Commission File Number: 000-30082 MERUS LABS INTERNATIONAL I |
|
| December 30, 2015 |
Merus Labs International Inc. Annual Report 2015 For the Years Ended September 30, 2015 and 2014 EX-99.2 3 v428058ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 Merus Labs International Inc. Annual Report 2015 For the Years Ended September 30, 2015 and 2014 Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of Merus Labs International Inc.: We have audited the accompanying consolidated financial statements of Merus Labs International Inc. and its subsidia |
|
| December 30, 2015 |
EX-99.1 2 v428058ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 ANNUAL INFORMATION FORM FOR THE YEAR-ENDED SEPTEMBER 30, 2015 DECEMBER 29, 2015 MERUS LABS INTERNATIONAL INC. 100 Wellington St. West, Suite 2110 Toronto, Ontario, Canada M5K 1H1 TABLE OF CONTENTS INTRODUCTORY NOTES 3 The Company 3 Date of Information 3 Currency 3 Cautionary Note Regarding Forward Looking Statements 3 CORPORATE STRUCTURE 6 Corp |
|
| December 9, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 7, 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (A |
|
| December 9, 2015 |
Merus Reports Fiscal 2015 Results and Provides Business Update Exhibit 99.1 Merus Reports Fiscal 2015 Results and Provides Business Update Revenue of $49.0 million, an 87% increase over fiscal 2014 Adjusted EBITDA of $32.6 million, a 144% increase over fiscal 2014 TORONTO, Dec. 7, 2015 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] is pleased to report its financial results for fiscal year ending September 30, 2015. |
|
| December 9, 2015 |
Merus Labs International Inc. Annual Report 2015 For the Years Ended September 30, 2015 and 2014 Exhibit 99.2 Merus Labs International Inc. Annual Report 2015 For the Years Ended September 30, 2015 and 2014 Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of Merus Labs International Inc.: We have audited the accompanying consolidated financial statements of Merus Labs International Inc. and its subsidiaries which comprise the consolidated stat |
|
| December 9, 2015 |
Exhibit 99.3 MERUS LABS INTERNATIONAL INC. MANAGEMENT?S DISCUSSION AND ANALYSIS For the years ended September 30, 2015 and 2014 The following section of our report sets forth Management?s Discussion and Analysis of the financial performance and condition of Merus Labs International Inc. (?the Company? or ?Merus?) for the year ended September 30, 2015 compared to the year ended September 30, 2014. |
|
| December 1, 2015 |
Merus Labs to Host Conference Call on Year End Results Exhibit 99.1 Merus Labs to Host Conference Call on Year End Results TORONTO, Dec. 1, 2015 /CNW/ - Merus Labs International Inc. (NASDAQ:MSLI; TSX:MSL) ("Merus" or "the Company") today announced it will release its fiscal year 2015 earnings after market close on Monday, December 7, 2015. Merus will hold a conference call at 8:30am ET on Tuesday, December 8, 2015 to discuss the results. The conferen |
|
| December 1, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 12015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Add |
|
| November 3, 2015 |
Merus Labs International FORM F-10/A F-10/A 1 formf10a.htm FORM F-10/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MERUS LABS INTERNATIONAL INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada 2834 Not Applicable (Province or other jurisdiction (Primary Standard Industrial (I.R.S. Employer o |
|
| October 23, 2015 |
EX-99.2 3 ex992.htm MERUS LABS INTERNATIONAL INC. - FINANCIALS Exhibit 99.2 Merus Labs International Inc. Financial Statements For the Nine Months Ended June 30, 2015 and 2014 Merus Labs International Inc. Consolidated Financial Statements June 30, 2015 (Expressed in Canadian Dollars) TABLE OF CONTENTS Page Report of Independent Auditor 3 Consolidated Statements of Financial Position as at June 30 |
|
| October 23, 2015 |
Merus Labs Announces Filing of Audited June 30, 2015 Financial Statements EX-99.1 2 ex991.htm NEWS RELEASE DATED OCTOBER 21, 2015 Exhibit 99.1 Merus Labs Announces Filing of Audited June 30, 2015 Financial Statements TORONTO, Oct. 21, 2015 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI], announced today that it has filed on SEDAR the audited financial statements of the Company for the nine months ended June 30, 2015 (the "Audite |
|
| October 23, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 |
|
| August 17, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4182986k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 15 |
|
| August 17, 2015 |
Exhibit 99.1 MERUS LABS INTERNATIONAL INC. MANAGEMENT?S DISCUSSION AND ANALYSIS For the three and nine months ended June 30, 2015 and 2014 The following section of our report sets forth Management?s Discussion and Analysis of the financial performance and condition of Merus Labs International Inc. (?the Company? or ?Merus?) for the three and nine months ended June 30, 2015 compared to the three an |
|
| August 14, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 |
|
| August 14, 2015 |
Merus Labs Reports Q3 2015 Results Exhibit 99.1 Merus Labs Reports Q3 2015 Results - Net revenues of $9.5 million, an increase of 32% over Q3/14 - Adjusted EBITDA of $6.4 million, an increase of 65% over Q3/14 - Company reaffirms full-year outlook and robust pipeline - Conference call at 8:30am ET August 11, 2015 TORONTO, Aug. 10, 2015 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] today a |
|
| July 13, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Address |
|
| July 13, 2015 |
Merus Labs Announces Filing of Preliminary Base Shelf Prospectus EX-99.1 2 ex991.htm NEWS RELEASE DATED JULY 10, 2015 Exhibit 99.1 Merus Labs Announces Filing of Preliminary Base Shelf Prospectus TORONTO, July 10, 2015 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI], announced today that it has filed a preliminary short form base shelf prospectus with the securities commissions in all provinces in Canada, other than Que |
|
| July 9, 2015 |
Merus Labs International FORM F-X F-X 1 formfx.htm FORM F-X UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing (“Filer”): Merus Labs International Inc. B. (1) This is [check one]: [X] an original filing for the Filer. [ ] an amended filing for the Filer. (2) Check the following box if you are filing the Form |
|
| July 9, 2015 |
Merus Labs International FORM F-10 Merus Labs International Inc. - Form F-10 - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-10 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 MERUS LABS INTERNATIONAL INC. (Exact name of Registrant as specified in its charter) British Columbia, Canada 2834 Not Applicable (Province or other jurisdiction (Primary Standard Industrial ( |
|
| June 25, 2015 |
FORM 51-102F3 MATERIAL CHANGE REPORT EX-99.4 5 exhibit99-4.htm EXHIBIT 99.4 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Merus Labs International Inc. (the “Company” or “Merus”) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 Item 2 Date of Material Change June 1, 2015 Item 3 News Release A news release was issued by the Company on June 1, 2015 and distributed through Marketwired |
|
| June 25, 2015 |
FORM 51-102F3 MATERIAL CHANGE REPORT EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Merus Labs International Inc. (the “Company” or “Merus”) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 Item 2 Date of Material Change September 23, 2014 Item 3 News Release A news release was issued by the Company on September 23, 2014 and distributed through |
|
| June 25, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 form6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2015 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toro |
|
| June 25, 2015 |
FORM 51-102F3 MATERIAL CHANGE REPORT Merus Labs International Inc.: Exhibit 99.3 - Filed by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Merus Labs International Inc. (the ?Company? or ?Merus?) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 Item 2 Date of Material Change May 22, 2015 and May 26, 2015 Item 3 News Release The news release announcing product acquis |
|
| June 25, 2015 |
FORM 51-102F3 MATERIAL CHANGE REPORT Merus Labs International Inc.: Exhibit 99.2 - Filed by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Merus Labs International Inc. (the ?Company? or ?Merus?) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 Item 2 Date of Material Change November 17, 2014 Item 3 News Release A news release was issued by the Company on November 1 |
|
| June 8, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Address |
|
| June 8, 2015 |
Merus Labs Provides an Update on German Reimbursement Review Exhibit 99.1 Merus Labs Provides an Update on German Reimbursement Review TORONTO, June 3, 2015 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI], is providing an update on the review of the German Federal Joint Committee (the "G-BA") related to Emselex? (Darifenacin). Last summer, the Company was informed by the G-BA of a plan to introduce a reimbursement c |
|
| June 1, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Address |
|
| June 1, 2015 |
Merus Labs International Inc. Announces Closing of Exercise of Over-Allotment Option EX-99.1 2 ex991.htm NEWS RELEASE DATED JUNE 1, 2015 Exhibit 99.1 Merus Labs International Inc. Announces Closing of Exercise of Over-Allotment Option TORONTO, June 1, 2015 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") (TSX: MSL, NASDAQ: MSLI) is pleased to announce today that the syndicate of investment dealers (the "Underwriters") has exercised the over-allotment option to purc |
|
| May 29, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Tor |
|
| May 29, 2015 |
Merus Labs to Present at Jefferies 2015 Healthcare Conference in New York EX-99.1 2 ex991.htm NEWS RELEASE DATED MAY 28, 2015 Exhibit 99.1 Merus Labs to Present at Jefferies 2015 Healthcare Conference in New York TORONTO, May 28, 2015 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI], a specialty pharmaceutical company, announced today that Barry Fishman, Chief Executive Officer is scheduled to present at the Jefferies 2015 Health |
|
| May 26, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Address o |
|
| May 26, 2015 |
Merus Labs Appoints Frank Rotmann VP & Head of European Operations Exhibit 99.1 Merus Labs Appoints Frank Rotmann VP & Head of European Operations TORONTO, May 26, 2015 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] is pleased to announce the appointment of Frank Rotmann as Vice President and Head of European Operations, effective today. Based in Zurich, Switzerland, Mr. Rotmann has over 20 years of experience in the pha |
|
| May 22, 2015 |
Merus Labs Acquires Specialty Product Rights in Multiple Countries Exhibit 99.1 Merus Labs Acquires Specialty Product Rights in Multiple Countries TORONTO, May 22, 2015 /CNW/ - Merus Labs International Inc.("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] is pleased to announce that one of its wholly owned subsidiaries has signed a definitive agreement to acquire the rights to manufacture, market, and sell two established specialty pharmaceutical products in ce |
|
| May 22, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Tor |
|
| May 14, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 v4107016k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 T |
|
| May 14, 2015 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.2 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Barry Fishman, Chief Executive Officer of Merus Labs International Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Merus Labs International Inc. (the ?issuer?) for the interim period ended March 31, 2015; 2. No misrepresentations |
|
| May 14, 2015 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Andrew Patient, Chief Financial Officer of Merus Labs International Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of Merus Labs International Inc. (the ?issuer?) for the interim period ended March 31, 2015; 2. No misrepresentation |
|
| May 14, 2015 |
Exhibit 99.1 MERUS LABS INTERNATIONAL INC. MANAGEMENT?S DISCUSSION AND ANALYSIS For the three and six months ended March 31, 2015 and 2014 The following section of our report sets forth Management?s Discussion and Analysis of the financial performance and condition of Merus Labs International Inc. (?the Company? or ?Merus?) for the three and six months ended March 31, 2015 compared to the three an |
|
| May 13, 2015 |
Merus Labs Reports Strong Q2 2015 Results Exhibit 99.1 Merus Labs Reports Strong Q2 2015 Results ? Net revenues of $12.7 million, an increase of 90% over Q2/14 ? Adjusted EBITDA of $9.4 million, an increase of 188% over Q2/14 ? Net income of $2.2 million, first full quarter of positive earnings TORONTO, May 13, 2015 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") [TSX: MSL, NASDAQ: MSLI] is pleased to announce financial r |
|
| May 13, 2015 |
Exhibit 99.1 UNDERWRITING AGREEMENT April 16, 2015 Merus Labs International Inc. 100 Wellington St. West Suite 2110, P.O. Box 151 Toronto, ON M5K 1H1 Attention: Barry Fishman, Chief Executive Officer & Director Dear Sirs/Mesdames: Clarus Securities Inc. and Cormark Securities Inc. (collectively, the ?Co-Lead Underwriters?), together with Canaccord Genuity Corp., Laurentian Bank Securities Inc., GM |
|
| May 13, 2015 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Merus Labs International Inc. (the ?Company? or ?Merus?) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 Item 2 Date of Material Change April 30, 2015 Item 3 News Release A news release was issued by the Company on April 30, 2015 and distributed through Marketwired and filed on SEDAR. I |
|
| May 13, 2015 |
MERUS LABS REPORTS STRONG Q2 2015 RESULTS - Net revenues of $12.7 million, an increase of 90% over Q2/14 - Adjusted EBITDA of $9.4 million, an increase of 188% over Q2/14 - Net income of $2.2 million, first full quarter of positive earnings Toronto, May 13, 2015 - Merus Labs International Inc. ("Merus" or the “Company") [TSX: MSL, NASDAQ: MSLI] is pleased to announce financial results for its seco |
|
| May 13, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Tor |
|
| May 13, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2015 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 To |
|
| May 12, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Address o |
|
| May 12, 2015 |
Merus Labs to Host Q2 Results Conference Call EX-99.1 2 ex991.htm NEWS RELEASE DATED MAY 11, 2015 Exhibit 99.1 Merus Labs to Host Q2 Results Conference Call TORONTO, May 11, 2015 /CNW/ - Merus Labs International Inc. (NASDAQ:MSLI; TSX:MSL) ("Merus" or "the Company") today announced it will release its second quarter 2015 earnings after market close on Wednesday, May 13, 2015. Merus will hold a conference call at 8:30am ET on Thursday, May 14, |
|
| May 11, 2015 |
MSLI / Merus Labs International Inc / 1832 Asset Management L.P. - FORM SC 13G Passive Investment Merus Labs International Inc.: Schedule 13G - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Initial Filing)* MERUS LABS INTERNATIONAL INC. (Name of Issuer) COMMON SHARES (Title of Class of Securities) 59047R101 (CUSIP Number) April 30, 2015 (Date of Event Which Requires Filing of this Statem |
|
| April 30, 2015 |
Merus Labs International Inc. announces closing of C$60.0 million bought deal financing EX-99.1 2 ex991.htm NEWS RELEASE DATED APRIL 30, 2015 Exhibit 99.1 Merus Labs International Inc. announces closing of C$60.0 million bought deal financing TORONTO, April 30, 2015 /CNW/ - Merus Labs International Inc. ("Merus" or the "Company") (TSX: MSL, NASDAQ: MSLI) is pleased to announce today the closing of its previously announced bought deal financing with a syndicate of investment dealers ( |
|
| April 30, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of APRIL 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 T |
|
| April 30, 2015 |
MERUS LABS INTERNATIONAL INC. ANNOUNCES CLOSING OF $60.0 MILLION BOUGHT DEAL FINANCING NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, April 30, 2015 - Merus Labs International Inc. (“Merus” or the “Company”) (TSX: MSL, NASDAQ: MSLI) is pleased to announce today the closing of its previously announced bought deal financing with a syndicate of inves |
|
| April 21, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of APRIL 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 T |
|
| April 21, 2015 |
MERUS LABS INTERNATIONAL INC. (the “Company”) Exhibit 99.1 Incorporation number: BC0951535 MERUS LABS INTERNATIONAL INC. (the ?Company?) ARTICLES 1. Interpretation 2. Shares and Share Certificates 3. Issue of Shares 4. Share Registers 5. Share Transfers 6. Transmission of Shares 7. Purchase of Shares 8. Borrowing Powers 9. Alterations 10. Meetings of Shareholders 11. Proceedings at Meetings of Shareholders 12. Votes of Shareholders 13. Direct |
|
| April 13, 2015 |
MERUS LABS INTERNATIONAL INC. ENTERS INTO A BOUGHT DEAL FOR GROSS PROCEEDS OF $60 MILLION Exhibit 99.1 MERUS LABS INTERNATIONAL INC. ENTERS INTO A BOUGHT DEAL FOR GROSS PROCEEDS OF $60 MILLION Toronto, April 13, 2015 - Merus Labs International Inc. (TSX:MSL) (NASDAQ:MSLI) ("MSL" or the "Company") has entered into an agreement with a syndicate of underwriters (the "Underwriters"), pursuant to which the Underwriters have agreed to purchase, on a bought deal basis, 19,672,200 common share |
|
| April 13, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of APRIL 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 T |
|
| April 7, 2015 |
EX-99.1 2 ex991.htm REPORT OF VOTING RESULTS Exhibit 99.1 Merus Labs International Inc. March 31, 2015 British Columbia Securities Commission Alberta Securities Commission Saskatchewan Financial Services Commission Manitoba Securities Commission Ontario Securities Commission Autorité des marchés financiers New Brunswick Securities Commission Prince Edward Island Office of the Attorney General Dear |
|
| April 7, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of MARCH 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 T |
|
| March 30, 2015 |
Merus Labs Appoints New Director and Provides European Update Exhibit 99.1 Merus Labs Appoints New Director and Provides European Update TORONTO, March 27, 2015 /CNW/ - Merus Labs International Inc. (NASDAQ:MSLI; TSX:MSL) ("Merus" or "the Company") pleased to announce that Dr. Robert Bloch M.D. will join the Board of Directors effective today. Dr. Bloch is a European-based pharmaceutical industry veteran who has a proven track record of leading profitable gr |
|
| March 30, 2015 |
Merus Labs International FORM 6-K (Current Report of Foreign Issuer) 6-K 1 merus6k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of MARCH 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 T |
|
| March 11, 2015 |
Merus Labs International 6-K (Current Report of Foreign Issuer) 6-K 1 v4040156k.htm 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of MARCH 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toro |
|
| March 11, 2015 |
EX-99.2 3 v404015ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 MERUS LABS INTERNATIONAL INC. 100 Wellington Street West, #2110 Toronto, Ontario M5K 1H1 Telephone: (416) 593-3725 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING TO THE SHAREHOLDERS OF MERUS LABS INTERNATIONAL INC.: NOTICE IS HEREBY GIVEN that an annual general and special meeting (the “Meeting”) of the holders (the ”Shareholders”) of common shar |
|
| March 11, 2015 |
Exhibit 99.3 |
|
| March 11, 2015 |
Exhibit 99.1 Merus Labs International Inc. 100 Wellington St. West, Suite 2110 Toronto, Ontario M5K 1H1 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 26, 2015 AND INFORMATION CIRCULAR February 23, 2015 This document requires immediate attention. If you are in doubt as to how to deal with the documents or matters referred to in this Information Circular, you shoul |
|
| March 2, 2015 |
Merus Labs announces settlement of Canadian patent litigation Exhibit 99.1 Merus Labs announces settlement of Canadian patent litigation TORONTO, March 2, 2015 /CNW/ - Merus Labs International Inc. (NASDAQ:MSLI; TSX:MSL) ("Merus" or "the Company") announces that it has reached a settlement with Apotex Inc. related to the previously disclosed Canadian patent litigation on Enablex® (darifenacin hydrobromide). The terms of the settlement are confidential, and t |
|
| March 2, 2015 |
MSLI / Merus Labs International Inc 6-K - Current Report of Foreign Issuer - FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of MARCH 2015 Commission File No. 000-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellington St. West, Suite 2110 P.O. Box 151 Toronto, ON M5K 1H1 (Address |
|
| February 12, 2015 |
MSLI / Merus Labs International Inc 6-K - Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of JANUARY 2015 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Well |
|
| February 12, 2015 |
Merus Labs International Inc. - Exhibit 99.1 - Filed by newsfilecorp.com Merus Labs International Inc. First Quarter Report 2015 For the Three Months Ended December 31, 2014 and 2013 MERUS LABS INTERNATIONAL INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three months ended December 31, 2014 and 2013 The following section of our report sets forth Management’s Discussion and Analysis of the finan |
|
| February 12, 2015 |
MERUS LABS ANNOUNCES RECORD Q1 2015 RESULTS Merus Labs International Inc. - Exhibit 99.2 - Filed by newsfilecorp.com MERUS LABS ANNOUNCES RECORD Q1 2015 RESULTS - Net revenues of $10.6 million, an increase of 70% over Q1/14 - Adjusted EBITDA of $7.6 million, an increase of 166% over Q1/14 Toronto, February 11, 2015 - Merus Labs International Inc. ("Merus" or the “Company") [TSX: MSL, NASDAQ: MSLI] is pleased to announce today its financial |
|
| February 10, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| December 24, 2014 |
MSLI / Merus Labs International Inc / Goodwood Inc. Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G INFORMATION STATEMENT PURSUANT TO RULES 13d-1 AND 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 MERUS LABS INTERNATIONAL INC. |
|
| December 24, 2014 |
MSLI / Merus Labs International Inc F-X - - FORM F-X Merus Labs International Inc. - Form F-X - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing (“Filer”): Merus Labs International Inc. B. (1) This is [check one]: [X] an original filing for the Filer. [ ] an amended filing for the Filer. (2) Check t |
|
| December 23, 2014 |
Annual Information Form of the Company for the year ended September 30, 2014 (the AIF) Merus Labs International Inc. - Exhibit 99.1 - Filed by newsfilecorp.com ANNUAL INFORMATION FORM FOR THE YEAR-ENDED SEPTEMBER 30, 2014 DECEMBER 22, 2014 MERUS LABS INTERNATIONAL INC. 100 Wellington St. West, Suite 2110 Toronto, Ontario, Canada M5K 1H1 - 2 - TABLE OF CONTENTS INTRODUCTORY NOTES 1 THE COMPANY 1 DATE OF INFORMATION 1 CURRENCY 1 CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS 1 C |
|
| December 23, 2014 |
Merus Labs International Inc.: Exhibit 99.1 - Filed by newsfilecorp.com Merus Labs International Inc. Annual Report 2014 For the Years Ended September 30, 2014 and 2013 Deloitte LLP 5140 Yonge Street Suite 1700 Toronto ON M2N 6L7 Canada Tel: 416-601-6150 Fax: 416-601-6151 www.deloitte.ca Report of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of Merus Lab |
|
| December 23, 2014 |
Merus Labs International Inc.: Exhibit 99.1 - Filed by newsfilecorp.com Merus Labs International Inc. Annual Report 2014 For the Years Ended September 30, 2014 and 2013 MERUS LABS INTERNATIONAL INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the year ended September 30, 2014 and 2013 The following section of our annual report sets forth Management’s Discussion and Analysis of the financial performan |
|
| December 23, 2014 |
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Exchange Act (1) Merus Labs International Inc. - Exhibit 99.4 - Filed by newsfilecorp.com EXHIBIT 99.4 CERTIFICATION I, Barry Fishman, certify that: (1) I have reviewed this Annual Report on Form 40-F of Merus Labs International Inc. for the year ended September 30, 2014. (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to ma |
|
| December 23, 2014 |
Merus Labs International Inc. - Exhibit 99.6 - Filed by newsfilecorp.com EXHIBIT 99.6 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Barry Fishman, Chief Executive Officer of Merus Labs International Inc. (the “Company”), hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-O |
|
| December 23, 2014 |
Consent of Deloitte LLP dated December 22, 2014 (1) Merus Labs International Inc. - Exhibit 99.8 - Filed by newsfilecorp.com Deloitte LLP 5140 Yonge Street Suite 1700 Toronto ON M2N 6L7 Canada Tel: 416-601-6150 Fax: 416-601-6151 www.deloitte.ca Consent of Independent Registered Public Accounting Firm We consent to the use of our report dated December 30, 2013 relating to the consolidated financial statements of Merus Labs International Inc. (“the C |
|
| December 23, 2014 |
Merus Labs International Inc. - Exhibit 99.7 - Filed by newsfilecorp.com EXHIBIT 99.7 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 I, Andrew Patient, Chief Financial Officer of Merus Labs International Inc. (the “Company”), hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes- |
|
| December 23, 2014 |
MSLI / Merus Labs International Inc 40-F - - FORM 40-F Merus Labs International Inc. - Form 40-F - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F [ ] REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OR [X] ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: September 30, 2014 Commission File Nu |
|
| December 23, 2014 |
Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Exchange Act (1) Merus Labs International Inc. - Exhibit 99.5 - Filed by newsfilecorp.com EXHIBIT 99.5 CERTIFICATION I, Andrew Patient, certify that: (1) I have reviewed this Annual Report on Form 40-F of Merus Labs International Inc. for the year ended September 30, 2014. (2) Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to m |
|
| December 23, 2014 |
Consent of MNP LLP dated December 22, 2014 (1) Merus Labs International Inc. - Exhibit 99.9 - Filed by newsfilecorp.com Consent of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders of Merus Labs International Inc. We consent to the inclusion in this annual report on Form 40-F of our Independent Auditors’ Report of Registered Public Accounting Firm dated December 18, 2014 on the consolidated financial stat |
|
| December 19, 2014 |
MSLI / Merus Labs International Inc 6-K - Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2014 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wel |
|
| December 19, 2014 |
Merus Labs International Inc. Annual Report 2014 For the Years Ended September 30, 2014 and 2013 EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Merus Labs International Inc. Annual Report 2014 For the Years Ended September 30, 2014 and 2013 MERUS LABS INTERNATIONAL INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the year ended September 30, 2014 and 2013 The following section of our annual report sets forth Management’s Discussion and Analysis of the financial performance and condition of Merus Labs In |
|
| December 19, 2014 |
FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE Merus Labs International Inc.: Exhibit 99.2 - Filed by newsfilecorp.com FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Barry Fishman, Chief Executive Officer of Merus Labs International Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are inco |
|
| December 19, 2014 |
FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE EX-99.3 4 exhibit99-3.htm EXHIBIT 99.3 FORM 52-109F1 CERTIFICATION OF ANNUAL FILINGS FULL CERTIFICATE I, Andrew Patient, Chief Financial Officer of Merus Labs International Inc., certify the following: 1. Review: I have reviewed the AIF, if any, annual financial statements and annual MD&A, including, for greater certainty, all documents and information that are incorporated by reference in the AIF |
|
| September 22, 2014 |
Merus Labs International Inc.: Exhibit 99.1 - Filed by newsfilecorp.com MERUS LABS INTERNATIONAL INC. as Borrower - and - BANK OF MONTREAL CIT FINANCIAL LTD. EXPORT DEVELOPMENT CANADA and LAURENTIAN BANK OF CANADA as Lenders - and - BANK OF MONTREAL and CIT GROUP SECURITIES (CANADA) INC. as Co-Lead Arrangers - and - BANK OF MONTREAL, as Administrative Agent CREDIT AGREEMENT September 5, 2014 TABLE |
|
| September 22, 2014 |
MSLI / Merus Labs International Inc 6-K - Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2014 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 We |
|
| September 22, 2014 |
FORM 51-102F3 MATERIAL CHANGE REPORT Merus Labs International Inc.: Exhibit 99.3 - Filed by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Merus Labs International Inc. (the “Company” or “Merus”) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 Item 2 Date of Material Change September 8, 2014 Item 3 News Release A news release was issued by the Company on September |
|
| September 22, 2014 |
Merus Labs International Inc.: Exhibit 99.4 - Filed by newsfilecorp.com ASSET PURCHASE AGREEMENT between NOVARTIS AG NOVARTIS PHARMA AG AND MERUS LABS LUXCO SARL MERUS LABS INTERNATIONAL INC. TABLE OF CONTENTS 1. DEFINITIONS AND INTERPRETATION 4 2. SALE AND TRANSFER OF ASSETS 9 3. GRANT OF LICENSES 10 4. ASSUMED LIABILITIES AND EXCLUDED LIABILITIES 10 5. OBLIGATIONS OF THE PURCHASER 11 6. TRANSITI |
|
| September 22, 2014 |
MERUS LABS INTERNATIONAL INC. ANNOUNCES ACQUISITION OF SINTROM ® Merus Labs International Inc.: Exhibit 99.2 - Filed by newsfilecorp.com MERUS LABS INTERNATIONAL INC. ANNOUNCES ACQUISITION OF SINTROM ® Toronto, September 8, 2014 - Merus Labs International Inc. (“Merus” or the “Company”) [TSX: MSL, NASDAQ: MSLI] is pleased to announce that one of its wholly owned subsidiaries has acquired from Novartis AG (“Novartis”), in certain European countries, the rights t |
|
| August 28, 2014 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 MERUS LABS INTERNATIONAL INC. ANNOUNCES COMPLETION OF $7 MILLION FINANCING TRANSACTION WITH DACHA STRATEGIC METALS INC. Toronto, August 14, 2014 - Merus Labs International Inc. (“Merus” or the “Company”) [TSX: MSL, NASDAQ: MSLI] is pleased to announce that, further to its news release dated July 4, 2014, the Company has today completed the financing acquisiti |
|
| August 28, 2014 |
FORM 51-102F3 MATERIAL CHANGE REPORT EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Merus Labs International Inc. (the “Company” or “Merus”) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 Item 2 Date of Material Change August 14, 2014 Item 3 News Release A news release was issued by the Company on August 14, 2014 and distributed through Marke |
|
| August 28, 2014 |
MSLI / Merus Labs International Inc 6-K - Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2014 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wel |
|
| August 14, 2014 |
I, Elie Farah, Chief Executive Officer EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Elie Farah, Chief Executive Officer of Merus Labs International Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Merus Labs International Inc. (the “issuer”) for the interim period ended June 30, 2014; 2. |
|
| August 14, 2014 |
MSLI / Merus Labs International Inc 6-K - Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2014 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Well |
|
| August 14, 2014 |
MERUS LABS INTERNATIONAL INC. ANNOUNCES THIRD QUARTER RESULTS FOR FISCAL 2014 EX-99.4 5 exhibit99-4.htm EXHIBIT 99.4 MERUS LABS INTERNATIONAL INC. ANNOUNCES THIRD QUARTER RESULTS FOR FISCAL 2014 Toronto, August 12, 2014 - Merus Labs International Inc. ("Merus" or the “Company") [TSX: MSL, NASDAQ: MSLI] is pleased to announce today its financial results for the third quarter of fiscal 2014. Revenues for the three months ended June 30, 2014 were $7,184,909, which were compris |
|
| August 14, 2014 |
I, Andrew Patient, Chief Financial Officer Merus Labs International Inc.: Exhibit 99.3 - Filed by newsfilecorp.com FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Andrew Patient, Chief Financial Officer of Merus Labs International Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Merus Labs International Inc. (the “issuer”) for the i |
|
| August 14, 2014 |
EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 Merus Labs International Inc. Third Quarter Report 2014 For the Three and Nine Months Ended June 30, 2014 and 2013 MERUS LABS INTERNATIONAL INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three and nine months ended June 30, 2014 and 2013 The following section of our annual report sets forth Management’s Discussion and Analysis of the financial performance |
|
| August 11, 2014 |
MERUS LABS INTERNATIONAL INC. SUBSIDIARY SIGNS PRODUCT ACQUISITION LETTER OF INTENT EX-99.3 4 exhibit99-3.htm EXHIBIT 99.3 MERUS LABS INTERNATIONAL INC. SUBSIDIARY SIGNS PRODUCT ACQUISITION LETTER OF INTENT Toronto, August 7, 2014 – Merus Labs International Inc. (“Merus” or the “Company”) [TSX: MSL, NASDAQ: MSLI] is pleased to announce today that one of its wholly owned subsidiaries has signed a letter of intent to acquire the rights to manufacture, market, and sell a branded pre |
|
| August 11, 2014 |
MERUS LABS INTERNATIONAL INC. 100 Wellington Street West, Suite 2110 Toronto, Ontario M5K 1H1 Merus Labs International Inc. - Exhibit 99.1 - Filed by newsfilecorp.com EXECUTION COPY MERUS LABS INTERNATIONAL INC. 100 Wellington Street West, Suite 2110 Toronto, Ontario M5K 1H1 July 4, 2014 CONFIDENTIAL DACHA STRATEGIC METALS INC. 212 King Street West, Suite 201 Toronto, Ontario M5H 1K5 Attn: Mr. Peter Puccetti, Chief Executive Officer Dear Sirs: Re: Acquisition Agreement We write further to |
|
| August 11, 2014 |
MERUS LABS INTERNATIONAL INC. ANNOUNCES CONVERSION OF $10 MILLION CONVERTIBLE DEBENTURES EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 MERUS LABS INTERNATIONAL INC. ANNOUNCES CONVERSION OF $10 MILLION CONVERTIBLE DEBENTURES Toronto, July 17, 2014 - Merus Labs International Inc. (“Merus” or the “Company”) [TSX: MSL, NASDAQ: MSLI] is pleased to announce today that the Company has exercised its right to convert the $10 million unsecured convertible debentures (the “Convertible Debentures”) issu |
|
| August 11, 2014 |
MSLI / Merus Labs International Inc 6-K - Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc. -Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2014 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Well |
|
| July 15, 2014 |
EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 July 11, 2014 British Columbia Securities Commission Ontario Securities Commission Autorité des marchés financiers Alberta Securities Commission Financial and Consumer Affairs Authority of Saskatchewan Manitoba Securities Commission New Brunswick Securities Commission Prince Edward Island Securities Office Dear Sirs/Mesdames: RE: Notice of Change of Auditor - |
|
| July 15, 2014 |
EX-99.3 4 exhibit99-3.htm EXHIBIT 99.3 Deloitte LLP 5140 Yonge Street Suite 1700 Toronto ON M2N 6L7 Canada Tel: 416-601-6150 Fax: 416-601 -6440 www.deloitte.ca TO: British Columbia Securities Commission Ontario Securities Commission Autorité des marchés financiers Alberta Securities Commission Financial and Consumer Affairs Authority of Saskatchewan Manitoba Securities Commission New Brunswick Sec |
|
| July 15, 2014 |
MSLI / Merus Labs International Inc 6-K - Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc.: Form 6K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2014 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Welling |
|
| July 15, 2014 |
FORM 51-102F3 MATERIAL CHANGE REPORT EX-99.5 6 exhibit99-5.htm EXHIBIT 99.5 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Merus Labs International Inc. (the “Company” or “Merus”) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 Item 2 Date of Material Change July 11, 2014 Item 3 News Release A news release was issued by the Company on July 11, 2014 and distributed through Marketwir |
|
| July 15, 2014 |
MERUS LABS INTERNATIONAL INC. ANNOUNCES CLOSING OF $10 MILLION PREFERRED SHARE FINANCING EX-99.4 5 exhibit99-4.htm EXHIBIT 99.4 MERUS LABS INTERNATIONAL INC. ANNOUNCES CLOSING OF $10 MILLION PREFERRED SHARE FINANCING Toronto, July 11, 2014 - Merus Labs International Inc. (“Merus” or the “Company”) [TSX: MSL, NASDAQ: MSLI] is pleased to announce today that the Company has completed its previously announced private placement issuance of $10 million of Series A convertible preferred shar |
|
| July 10, 2014 |
MSLI / Merus Labs International Inc 6-K - Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc. - Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2014 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Welli |
|
| July 10, 2014 |
EX-99.3 4 exhibit99-3.htm EXHIBIT 99.3 MERUS LABS INTERNATIONAL INC. ANNOUNCES CLOSING OF $31.3 MILLION BOUGHT DEAL FINANCING, INCLUDING EXERCISE OF OVER-ALLOTMENT OPTION Toronto, June 19, 2014 - Merus Labs International Inc. ("Merus" or the “Company") (TSX: MSL, NASDAQ: MSLI) is pleased to announce today the closing of its previously announced bought deal financing with a syndicate of investment |
|
| July 10, 2014 |
FORM 51-102F3 MATERIAL CHANGE REPORT EX-99.4 5 exhibit99-4.htm EXHIBIT 99.4 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Merus Labs International Inc. (the “Company” or “Merus”) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 Item 2 Date of Material Change June 19, 2014 Item 3 News Release A news release was issued by the Company on June 19, 2014 and distributed through Marketwir |
|
| July 10, 2014 |
EX-99.2 3 exhibit99-2.htm EXHIBIT 99.2 EXECUTION COPY UNDERWRITING AGREEMENT June 13, 2014 Merus Labs International Inc. 100 Wellington St. West Suite 2110, P.O. Box 151 Toronto, ON M5K 1H1 Attention: Elie Farah, Chief Executive Officer and President Dear Sirs/Mesdames: Canaccord Genuity Corp., Clarus Securities Inc. and Cormark Securities Inc. (collectively, the “Co-Lead Underwriters”), together |
|
| June 12, 2014 |
Merus Labs International Inc. Announces $22.1 Million Bought Deal Financing Merus Labs International Inc.: Exhibit 99.1 - Filed by newsfilecorp.com Merus Labs International Inc. Announces $22.1 Million Bought Deal Financing Toronto, June 11, 2014 - Merus Labs International Inc. ("the Company" or "Merus") [TSX: MSL; NASDAQ: MSLI] is pleased to announce that it has entered into an agreement with a syndicate of investment dealers (the "Underwriters") pursuant to which the Un |
|
| June 12, 2014 |
Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2014 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellin |
|
| June 12, 2014 |
Merus Labs International Inc. Announces Increase to Previously Announced Financing Merus Labs International Inc.: Exhibit 99.2 - Filed by newsfilecorp.com Merus Labs International Inc. Announces Increase to Previously Announced Financing Toronto, June 12, 2014 - Merus Labs International Inc. ("the Company" or "Merus") [TSX: MSL; NASDAQ: MSLI] is pleased to announce that it has amended the terms of the previously announced bought deal public offering with a syndicate of investmen |
|
| June 11, 2014 |
FORM 51-102F3 MATERIAL CHANGE REPORT Merus Labs International Inc.: Exhibit 99.2 - Filed by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Merus Labs International Inc. (the “Company” or “Merus”) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 Item 2 Date of Material Change June 10, 2014 Item 3 News Release A news release was issued by the Company on June 10, 2014 |
|
| June 11, 2014 |
Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2014 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Wellin |
|
| June 11, 2014 |
Merus Labs International Inc.: Exhibit 99.3 - Filed by newsfilecorp.com FORM OF SERIES A PREFERRED SHARE SUBSCRIPTION AGREEMENT MERUS LABS INTERNATIONAL INC. SERIES A PREFERRED SHARES PRIVATE PLACEMENT SUBSCRIPTION AGREEMENT The undersigned (the Subscriber) hereby irrevocably subscribes for and agrees to purchase from Merus Labs International Inc. (the Issuer) the number of Series A Preferred |
|
| June 11, 2014 |
MERUS LABS INTERNATIONAL INC ANNOUNCES AGGREGATE $21 MILLION FINANCING TRANSACTIONS Merus Labs International Inc.: Exhibit 99.1 - Filed by newsfilecorp.com MERUS LABS INTERNATIONAL INC ANNOUNCES AGGREGATE $21 MILLION FINANCING TRANSACTIONS Toronto, June 10, 2014 - Merus Labs International Inc. (“Merus” or the “Company”) [TSX: MSL, NASDAQ: MSLI] is pleased to announce today that the Company has entered into a private placement subscription agreement to issue $10 million of Series |
|
| June 11, 2014 |
MERUS LABS INTERNATIONAL INC. 100 Wellington Street West, Suite 2110 Toronto, Ontario M5K 1H1 Merus Labs International Inc.: Exhibit 99.4 - Filed by newsfilecorp.com MERUS LABS INTERNATIONAL INC. 100 Wellington Street West, Suite 2110 Toronto, Ontario M5K 1H1 June 10, 2014 CONFIDENTIAL DACHA STRATEGIC METALS INC. 212 King Street West, Suite 201 Toronto, Ontario M5H 1K5 Attn: Mr. Peter Puccetti, Chief Executive Officer Dear Sirs: The purpose of this Letter Agreement is to confirm the terms |
|
| May 16, 2014 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Merus Labs International Inc.: Exhibit 99.3 - Filed by newsfilecorp.com FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Andrew Patient, Chief Financial Officer of Merus Labs International Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Merus Labs International Inc. (the “issuer”) for the i |
|
| May 16, 2014 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Merus Labs International Inc.: Exhibit 99.2 - Filed by newsfilecorp.com FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Elie Farah, Chief Executive Officer of Merus Labs International Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of Merus Labs International Inc. (the “issuer”) for the inter |
|
| May 16, 2014 |
Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2014 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Welling |
|
| May 16, 2014 |
Merus Labs International Inc.: Exhibit 99.1 - Filed by newsfilecorp.com Merus Labs International Inc. Second Quarter Report 2014 For the Three and Six Months Ended March 31, 2014 and 2013 MERUS LABS INTERNATIONAL INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three and six months ended March 31, 2014 and 2013 The following section of our annual report sets forth Management’s Discussion and Anal |
|
| April 4, 2014 |
MERUS LABS INTERNATIONAL INC. ANNOUNCES CLOSING ON FULL EXERCISE OF OVER-ALLOTMENT OPTION EX-99.1 2 exhibit99-1.htm EXHIBIT 99.1 MERUS LABS INTERNATIONAL INC. ANNOUNCES CLOSING ON FULL EXERCISE OF OVER-ALLOTMENT OPTION Toronto, March 31, 2014 - Merus Labs International Inc. ("Merus" or the “Company") (TSX: MSL, NASDAQ: MSLI) is pleased to announce today that the syndicate of investment dealers (the "Underwriters") has exercised in full the over-allotment option to purchase 1,764,750 co |
|
| April 4, 2014 |
Merus Labs International Inc.: Exhibit 99.2 - Filed by newsfilecorp.com MERUS LABS INTERNATIONAL INC. April 1, 2014 British Columbia Securities Commission Alberta Securities Commission Saskatchewan Financial Services Commission Manitoba Securities Commission Ontario Securities Commission Autorité des marchés financiers New Brunswick Securities Commission Prince Edward Island Office of the Attorney |
|
| April 4, 2014 |
Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2014 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Welli |
|
| April 4, 2014 |
FORM 51-102F3 MATERIAL CHANGE REPORT Merus Labs International Inc.: Exhibit 99.3 - Filed by newsfilecorp.com FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Merus Labs International Inc. (the “Company” or “Merus”) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 Item 2 Date of Material Change March 31, 2014 Item 3 News Release A news release was issued by the Company on March 31, 201 |
|
| March 28, 2014 |
Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of MARCH, 2014 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Welli |
|
| March 28, 2014 |
Merus Labs International Inc. - Exhibit 99.3 - Filed by newsfilecorp.com MERUS LABS INTERNATIONAL INC. COMPLETES $20 MILLION BOUGHT DEAL FINANCING NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Toronto, March 25, 2014 - Merus Labs International Inc. ("Merus" or the “Company") (TSX: MSL, NASDAQ: MSLI) is pleased to announce today the closing of its previous |
|
| March 28, 2014 |
Merus Labs International Inc. Announces $20 Million Bought Deal Financing Merus Labs International Inc. - Exhibit 99.1 - Filed by newsfilecorp.com Merus Labs International Inc. Announces $20 Million Bought Deal Financing Toronto, Ontario – March 13, 2014 – Merus Labs International Inc. (TSX: MSL, NASDAQ: MSLI) (“the Company” or “Merus”) is pleased to announce that it has entered into an agreement with a syndicate of investment dealers co-led by Cormark Securities Inc., |
|
| March 28, 2014 |
Merus Labs International Inc. - Exhibit 99.2 - Filed by newsfilecorp.com EXECUTION COPY UNDERWRITING AGREEMENT March 17, 2014 Merus Labs International Inc. 100 Wellington St. West Suite 2110, P.O. Box 151 Toronto, ON M5K 1H1 Attention: Elie Farah, Chief Executive Officer and President Dear Sirs/Mesdames: Cormark Securities Inc., Canaccord Genuity Corp. and Clarus Securities Inc. (collectively, the |
|
| March 28, 2014 |
FORM 51-102F3 MATERIAL CHANGE REPORT EX-99.4 5 exhibit99-4.htm MATERIAL CHANGE REPORT DATED MARCH 25, 2014 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1 Name and Address of Company Merus Labs International Inc. (the “Company” or “Merus”) 100 Wellington Street West Suite 2110, PO Box 151 Toronto, Ontario, M5K 1H1 Item 2 Date of Material Change March 25, 2014 Item 3 News Release A news release was issued by the Company on March 25, 2014 |
|
| March 11, 2014 |
Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2014 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 Welli |
|
| March 11, 2014 |
Merus Labs International Inc.: Exhibit 99.3 - Filed by newsfilecorp.com Exhibit 99.3 |
|
| March 11, 2014 |
Merus Labs International Inc.: Exhibit 99.1 - Filed by newsfilecorp.com Exhibit 99.1 Merus Labs International Inc. 100 Wellington St. West, Suite 2110 Toronto, Ontario M5K 1H1 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING OF SHAREHOLDERS TO BE HELD ON MARCH 27, 2014 AND INFORMATION CIRCULAR February 25, 2014 This document requires immediate attention. If you are in doubt as to how to deal with the |
|
| March 11, 2014 |
Merus Labs International Inc.: Exhibit 99.2 - Filed by newsfilecorp.com Exhibit 99.2 MERUS LABS INTERNATIONAL INC. 100 Wellington Street West, #2110 Toronto, Ontario M5K 1H1 Telephone: (416) 593-3701 NOTICE OF ANNUAL GENERAL AND SPECIAL MEETING TO THE SHAREHOLDERS OF MERUS LABS INTERNATIONAL INC.: NOTICE IS HEREBY GIVEN that an annual general and special meeting (the “Meeting”) of the holders (the |
|
| March 11, 2014 |
Merus Labs International Inc.: Exhibit 99.4 - Filed by newsfilecorp.com CERTIFICATE Reference is made to the Annual General and Special Meeting of holders of Common Shares in the capital of Merus Labs International Inc. (the “Corporation”) scheduled to be held on March 27, 2014 at 10:00am (the “Meeting”). I, Andrew Patient, Chief Financial Officer of the Corporation hereby certify in my capacity a |
|
| February 18, 2014 |
Merus Labs International Inc.: Exhibit 99.1 - Filed by newsfilecorp.com Merus Labs International Inc. First Quarter Report 2014 For the Three Months Ended December 31, 2013 and 2012 MERUS LABS INTERNATIONAL INC. MANAGEMENT’S DISCUSSION AND ANALYSIS For the three months ended December 31, 2013 and 2012 The following section of our annual report sets forth Management’s Discussion and Analysis of the |
|
| February 18, 2014 |
Current Report of Foreign Issuer - FORM 6-K Merus Labs International Inc.: Form 6-K - Filed by newsfilecorp.com UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2014 Commission File No. 00-30082 MERUS LABS INTERNATIONAL INC. (Translation of registrant's name into English) 100 We |
|
| February 6, 2014 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
